Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 3Uterine Cervical Neoplasms 2Vaginal Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Lung Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma 1Adenocarcinoma 1

Interventions

Cisplatin 5nimotuzumab 2X-Rays 2Radiotherapy 2Magnetic Resonance Spectroscopy 2trifluridine tipiracil drug combination 1sargramostim 1palladium-bacteriopheophorbide 1padeliporfin 1imgatuzumab 1galactomannan 1futuximab 1fluoromisonidazole 1capmatinib 1cabozantinib 1Tomography, Optical Coherence 1Standard of Care 1Specimen Handling 1Ramucirumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Practice Guidelines as Topic 1Platinum 1Nivolumab 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Mitomycin 1LMB-100 1Ipilimumab 1Interviews as Topic 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma × Brachytherapy × Clear all
NCT01301612 2014-07-14

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Eurofarma Laboratorios S.A.

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡